An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Roche
- 03 Nov 2023 Planned End Date changed from 31 Aug 2024 to 21 Jun 2025.
- 03 Nov 2023 Planned primary completion date changed from 31 Aug 2024 to 21 Jun 2025.
- 03 Nov 2023 Status changed from recruiting to active, no longer recruiting.